<DOC>
	<DOCNO>NCT00919607</DOCNO>
	<brief_summary>The primary objective study evaluate pharmacokinetics XR quetiapine fumarate ( 300mg,600mg , 800mg once-daily ) Chinese schizophrenic patient .</brief_summary>
	<brief_title>Evaluate Pharmacokinetics Quetiapine Fumarate Chinese Schizophrenic Patients</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Men woman age 18 60 year inclusive Schizophrenia diagnosis Body Mass Index ( BMI ) 2027 kg/m2 ( inclusive ) Provision write informed consent initiation study AIDS &amp; hepatitis B History seizure disorder History episodic , idiopathic orthostatic hypotension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>quetiapine fumarate ( SEROQUEL ) extended-release ( XR ) China PK Study</keyword>
	<keyword>pharmacokinetics parameter</keyword>
</DOC>